U.S. flag

An official website of the United States government

NM_000061.3(BTK):c.1901G>C (p.Trp634Ser) AND X-linked agammaglobulinemia with growth hormone deficiency

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Apr 18, 2019
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001057527.9

Allele description [Variation Report for NM_000061.3(BTK):c.1901G>C (p.Trp634Ser)]

NM_000061.3(BTK):c.1901G>C (p.Trp634Ser)

Gene:
BTK:Bruton tyrosine kinase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Xq22.1
Genomic location:
Preferred name:
NM_000061.3(BTK):c.1901G>C (p.Trp634Ser)
HGVS:
  • NC_000023.11:g.101353201C>G
  • NG_009616.1:g.38024G>C
  • NG_011734.1:g.769G>C
  • NM_000061.3:c.1901G>CMANE SELECT
  • NM_001287344.2:c.2003G>C
  • NM_001287345.2:c.1373G>C
  • NP_000052.1:p.Trp634Ser
  • NP_001274273.1:p.Trp668Ser
  • NP_001274274.1:p.Trp458Ser
  • LRG_128t1:c.1901G>C
  • LRG_128:g.38024G>C
  • NC_000023.10:g.100608189C>G
  • NM_000061.2:c.1901G>C
Protein change:
W458S
Links:
dbSNP: rs1926352588
NCBI 1000 Genomes Browser:
rs1926352588
Molecular consequence:
  • NM_000061.3:c.1901G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001287344.2:c.2003G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001287345.2:c.1373G>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
X-linked agammaglobulinemia with growth hormone deficiency (IGHD3)
Synonyms:
IGHD III; Isolated growth hormone deficiency type 3; Growth hormone deficiency with hypogammaglobulinemia; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0010615; MedGen: C0472813; Orphanet: 631; OMIM: 307200

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001222025Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Likely pathogenic
(Apr 18, 2019)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001222025.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Trp634 amino acid residue in BTK. Other variant(s) that disrupt this residue have been observed in individuals with BTK-related conditions (PMID: 27512878, 25777788), which suggests that this may be a clinically significant amino acid residue. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed in an individual affected with X-linked agammaglobulinemia (PMID: 12655572). This variant is not present in population databases (ExAC no frequency). This sequence change replaces tryptophan with serine at codon 634 of the BTK protein (p.Trp634Ser). The tryptophan residue is highly conserved and there is a large physicochemical difference between tryptophan and serine.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024